Physician profile
Mark S Pascal
NPI 1700847373
$11,567.05
in general payments reported to CMS, 2019-2025
61 companies · $1,134 in 2025
The $1,134 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $1,258 · 2021: $1,952 · 2022: $2,020 · 2023: $1,901 · 2024: $1,907 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,229 · Consulting Fee: $394 · Education: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,229.48 |
| Consulting Fee | $393.75 |
| Education | $318.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,411.86 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Novartis Pharmaceuticals Corporation | $1,380.86 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,277.69 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Alexion Pharmaceuticals, INC. | $719.03 | 2019-2025 | Ultomiris |
| Pfizer INC. | $509.46 | 2019-2025 | |
| Astellas Pharma US INC | $496.36 | 2019-2025 | Xtandi, Padcev |
| Astrazeneca Pharmaceuticals Lp | $494.82 | 2019-2024 | Imfinzi, Tagrisso, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $483.06 | 2019-2025 | Opdivo |
| Amgen INC. | $464.03 | 2020-2023 | Lumakras |
| Incyte Corporation | $443.30 | 2019-2025 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $299.96 | 2020-2025 | Alunbrig, Vpriv |
| Bayer Healthcare Pharmaceuticals INC. | $280.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $228.62 | 2021-2024 | Libtayo |
| Janssen Biotech, INC. | $206.51 | 2019-2025 | Erleada, Akeega, Balversa |
| Eisai INC. | $204.36 | 2019-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Pascal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.